Levels of glycerophospholipids including phosphatidylcholines, lysophosphatidylcholines and plasmalogens were significantly reduced in COVID-19 patients with high IL-6 levels (Fig. 5 and Suppl. This evidence concerns the gene IL6 and COVID-19.